Clinical application of Digoxin Injection in patients with heart failure and rapid atrial fibrillation
WU Chunyan1 WANG Jianying2
1. Department of Cardiovascular Medicine，the Third Affiliated Hospital，Hengyang Medical School，University of South China，Hu′nan Province，Hengyang 421900，China；
2.Department of Neurology，the Third Affiliated Hospital，Hengyang Medical School，University of South China，Hu′nan Province，Hengyang 421900，China
Abstract：Objective To observe the efficacy of Digoxin Injection and Cedi-lanid in the treatment of patients with heart failure and rapid atrial fibrillation on the basis of conventional treatment. Methods A total of 100 patients with heart failure and rapid atrial fibrillation in the Third Affiliated Hospital of South China University from January 2020 to March 2021were selected as the research objects，and they were divided into the experimental group and the control group according to random number table method，with 50 cases in each group. All patients received conventional antiheart failure treatment，the experimental group was given Digoxin injection，the control group was given Cedi-lanid Injection for treatment. The therapeutic effect of heart failure，ventricular rate，N-terminal B-type natriuretic peptide(NT-proBNP)，creatinine value and glomerular filtration rate were compared between the two groups before and after treatment. Results The total effective rate of the experimental group was higher than that of the control group，and the difference was statistically significant (P＜0.05). The overall comparison of ventricular rate at each time point after treatment between the two groups was statistically significant (P＜0.05). The ventricular rate in the experimental group was lower than that in the control group 3 and 6 h after treatment，the difference was statistically significant (P＜0.05).There was no significant difference in ventricular rate between the two groups at 9，12，15，18，21，24 h after treatment(P＞0.05). There were no significant differences in creatinine and glomerular filtration rate between the two groups before treatment (P＞0.05). After treatment，the NT-proBNP of the two groups were lower than before treatment，and the NT-proBNP of the experimental group was lower than the control group，the differences were statistically significant(P＜0.05). Conclusion Digoxin Injection can effectively improve the symptoms of patients with heart failure and atrial fibrillation，control the ventricular rate，and is well tolerated. It has great clinical value in the treatment of such patients.
Shinohara M，Wada R，Yano K，et al.Comparison of Landiolol and Digoxin as an Intravenous Drug for Controlling the Heart Rate in Patients with Atrial Fibrillation and Severely Depressed Left Ventricular Function[J].Int Heart J，2020，61（5）：944-950.
[19]
Han X，Zhang S，Chen Z，et al.Cardiac biomarkers of heart failure in chronic kidney disease[J].Clin Chim Acta，2020，510：298-310.
[1]
Singh S，Moore H，Karasik PE，et al.Digoxin Initiation and Outcomes in Patients with Heart Failure（HFrEF and HFpEF）and Atrial Fibrillation[J].Am J Med，2020，133（12）：1460-1470.
[4]
Scalese MJ，Salvatore DJ.Role of Digoxin in Atrial Fibrillation[J].J Pharm Pract，2017，30（4）：434-440.
Ferrari F，Santander IRMF，Stein R.Digoxin in Atrial Fibrillation：An Old Topic Revisited[J].Curr Cardiol Rev，2020，16（2）：141-146.
[3]
Qamer SZ，Malik A，Bayoumi E，et al.Digoxin Use and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction[J].Am J Med，2019，132（11）：1311-1319.
[6]
Hindricks G，Potpara T，Dagres N，et al.ESC Scientific Document Group.2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery（EACTS）：The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology （ESC）Developed with the special contribution of the European Heart Rhythm Association （EHRA）of the ESC[J].Eur Heart J，2021，42（5）：373-498.
[7]
January CT，Wann LS，Calkins H，et al.2019 AHA/ACC/HRS Focwas given Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation[J].J Am Coll Cardiol，2019，74（1）：104-132.
[9]
Chang SS，Gao Y，Xia SJ，et al.Association between duration of digoxin use and adverse outcomes among Chinese patients with atrial fibrillation [J].Zhonghua Xin Xue Guan Bing Za Zhi，2020，48（9）：728-734.
[11]
Docherty KF，Jhund PS，Inzucchi SE，et al.Effects of dapagliflozin in DAPA-HF according to background heart failure therapy[J].Eur Heart J，2020，41（25）：2379-2392.
Ziff OJ，Kotecha D.Digoxin：The good and the bad [J].Trends Cardiovasc Med，2016，26（7）：585-595.
[14]
Lam PH，Packer M，Gill GS，et al.Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction[J].Am J Med，2020，133（10）：1187-1194.
[15]
Lopes RD，Rordorf R，De Ferrari GM，et al.ARISTOTLE Committees and Investigators.Digoxin and Mortality in Patients With Atrial Fibrillation[J].J Am Coll Cardiol，2018，71（10）：1063-1074.
[16]
Albert CL，Kamdar F，Hanna M.Contemporary Controversies in Digoxin Use in Systolic Heart Failure[J].Curr Heart Fail Rep，2016，13（5）：197-206.
[17]
Kelly JP，DeVore AD，Wu J，et al.Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction：Insights From Get With The Guidelines-Heart Failure[J].J Am Heart Assoc，2019，8（24）：e011560.
京公网安备 11010502046607号